<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889393</url>
  </required_header>
  <id_info>
    <org_study_id>20170189</org_study_id>
    <nct_id>NCT02889393</nct_id>
  </id_info>
  <brief_title>Teduglutide for Enterocutaneous Fistula (ECF)</brief_title>
  <official_title>Teduglutide for Treatment of Enterocutaneous Fistula (ECF) - a Pilot Study to Demonstrate Safety and Feasibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Dante Yeh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Teduglutide is safe and feasible to be&#xD;
      given for the treatment of enterocutaneous fistula (ECF). The hypothesis is that the drug&#xD;
      will be well tolerated and will improve the volume of daily ECF output as well as improve the&#xD;
      functional quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average 3-day Fistula Percent Volume</measure>
    <time_frame>Baseline, Up to 8 weeks</time_frame>
    <description>Percent fistula volume will be reported from the participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ceased Fistula Output</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>As evaluated by treating physician of having at least 1 ceased fistula output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by ASCQ-Me® v2.0 Social Functioning - Short Form</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Social Functioning - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the ASCQ-Me® v2.0 Sleep Impact - Short Form</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Sleep Impact - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the PROMIS Scale v1.2 - Global Health</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Patient Reported Outcome Measures Information Systems Global Health has a total score ranging from 10-50 with the higher score indicating a healthier status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Belly Pain 5a</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Belly Pain 5a questionnaire has a total score ranging from 1-25 with the lower score indicating a healthier status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Diarrhea 6a</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Diarrhea 6a questionnaire has a total score ranging from 1-30 with the lower score indicating a healthier status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Nausea and Vomiting 4a</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Nausea and Vomiting 4a questionnaire has a total score ranging from 1-20 with the lower score indicating a healthier status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the PROMIS Scale v2.0 - Ability to Participate in Social Roles and Activities - Short Form 8a</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Patient Reported Outcome Measures Information Systems (PROMIS) Ability to Participate in Social Roles and Activities - Short Form 8a questionnaire has a total score ranging from 8-40 with the lower score indicating a healthier status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Postoperative Fistula</condition>
  <arm_group>
    <arm_group_label>Standard of Care followed by Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teduglutide followed by Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Daily 0.05 mg/kg Teduglutide administered subcutaneously.</description>
    <arm_group_label>Standard of Care followed by Teduglutide</arm_group_label>
    <arm_group_label>Teduglutide followed by Standard of Care</arm_group_label>
    <other_name>Gattex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
    <arm_group_label>Standard of Care followed by Teduglutide</arm_group_label>
    <arm_group_label>Teduglutide followed by Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Enterocutaneous fistula (ECF) that could be secondary to volvulus, injury, prior&#xD;
             trauma or surgery, or vascular ischemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Perianal fistula&#xD;
&#xD;
          -  Clinical suspicion of inflammatory bowel disease&#xD;
&#xD;
          -  History of radiation enteritis or sprue (as defined by history)&#xD;
&#xD;
          -  Active (&lt;1 year) alcohol or drug abuse&#xD;
&#xD;
          -  Significant hepatic, or cardiac diseases as defined as:&#xD;
&#xD;
          -  Hepatic: aspartate aminotransferase (AST) &gt; 2 times upper limit of normal (10-40 U/L)&#xD;
&#xD;
          -  Cardiac: unstable angina or evidence of active myocardial ischemia (elevated troponin&#xD;
             level drawn by clinical suspicion)&#xD;
&#xD;
          -  Severe renal dysfunction: serum creatinine &gt; 2 times upper limit of normal (0.6-1.5&#xD;
             mg/dL)&#xD;
&#xD;
          -  Received glutamine less than 4 weeks prior to screening&#xD;
&#xD;
          -  Receiving growth factors (erythropoietin, granulocyte colony-stimulating factor,&#xD;
             granulo-cyte-macrophage colony stimulating factor, and human growth hormone)&#xD;
&#xD;
          -  Pregnancy or lactation (women of childbearing age will be excluded if they do not&#xD;
             agree to either complete sexual abstinence during the study or if they refuse to use&#xD;
             at least two forms of highly effective contraception such as oral contraception,&#xD;
             injectable or implantable contraception, vaginal rings, or intrauterine devices (IUD))&#xD;
&#xD;
          -  Active malignancy or suspicion for gastrointestinal malignancy on CT scan&#xD;
&#xD;
          -  Not capable of understanding or not willing to adhere to the study visit schedule and&#xD;
             drug administration requirements&#xD;
&#xD;
          -  Family history of intestinal malignancy (gastric, small intestine, colon)&#xD;
&#xD;
          -  Personal or family history of hereditary non-polyposis colorectal cancer, familial&#xD;
             adenomatous polyposis, first degree relative with colon cancer&#xD;
&#xD;
          -  Positive hemoccult (per rectum)&#xD;
&#xD;
          -  Abnormal baseline electrocardiogram (ECF) suggestive of congestive heart failure or&#xD;
             underlying cardiac disease&#xD;
&#xD;
          -  Taking oral benzodiazepines, barbiturates, or phenothiazines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel D Yeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009;2009:616054. doi: 10.1155/2009/616054. Epub 2009 Aug 20.</citation>
    <PMID>19707516</PMID>
  </reference>
  <reference>
    <citation>Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011 Jul;60(7):902-14. doi: 10.1136/gut.2010.218271. Epub 2011 Feb 11.</citation>
    <PMID>21317170</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <results_first_submitted>June 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Daniel Dante Yeh</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02889393/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care Followed by Teduglutide</title>
          <description>Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure.&#xD;
Teduglutide: Daily 0.05 mg/kg Teduglutide administered subcutaneously.&#xD;
Standard of Care: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
        </group>
        <group group_id="P2">
          <title>Teduglutide Followed by Standard of Care</title>
          <description>Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure&#xD;
Teduglutide: Daily 0.05 mg/kg Teduglutide administered subcutaneously.&#xD;
Standard of Care: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care Followed by Teduglutide</title>
          <description>Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure.&#xD;
Teduglutide: Daily 0.05 mg/kg Teduglutide administered subcutaneously.&#xD;
Standard of Care: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
        </group>
        <group group_id="B2">
          <title>Teduglutide Followed by Standard of Care</title>
          <description>Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.&#xD;
Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure&#xD;
Teduglutide: Daily 0.05 mg/kg Teduglutide administered subcutaneously.&#xD;
Standard of Care: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average 3-day Fistula Percent Volume</title>
        <description>Percent fistula volume will be reported from the participant</description>
        <time_frame>Baseline, Up to 8 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average 3-day Fistula Percent Volume</title>
          <description>Percent fistula volume will be reported from the participant</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>Percent change in fistula volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.33" spread="355.36"/>
                    <measurement group_id="O2" value="441.67" spread="824.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ceased Fistula Output</title>
        <description>As evaluated by treating physician of having at least 1 ceased fistula output</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Ceased fistula output was reported for all participants at the end of treatment after receiving both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants that received both standard of care and teduglutide interventions after a combined 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ceased Fistula Output</title>
          <description>As evaluated by treating physician of having at least 1 ceased fistula output</description>
          <population>Ceased fistula output was reported for all participants at the end of treatment after receiving both interventions.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by ASCQ-Me® v2.0 Social Functioning - Short Form</title>
        <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Social Functioning - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by ASCQ-Me® v2.0 Social Functioning - Short Form</title>
          <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Social Functioning - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status.</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="5.2"/>
                    <measurement group_id="O2" value="20" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the ASCQ-Me® v2.0 Sleep Impact - Short Form</title>
        <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Sleep Impact - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the ASCQ-Me® v2.0 Sleep Impact - Short Form</title>
          <description>Adult Sickle Cell Quality of Life Measurement (ASCQ-Me) Version 2.0 Sleep Impact - Short Form questionnaire has a total score ranging from 5-25 with the higher score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="1.3"/>
                    <measurement group_id="O2" value="19.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the PROMIS Scale v1.2 - Global Health</title>
        <description>Patient Reported Outcome Measures Information Systems Global Health has a total score ranging from 10-50 with the higher score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each. 1 participant in the teduglutide arm did not complete the global health questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the PROMIS Scale v1.2 - Global Health</title>
          <description>Patient Reported Outcome Measures Information Systems Global Health has a total score ranging from 10-50 with the higher score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each. 1 participant in the teduglutide arm did not complete the global health questionnaire.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="6.3"/>
                    <measurement group_id="O2" value="35" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Belly Pain 5a</title>
        <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Belly Pain 5a questionnaire has a total score ranging from 1-25 with the lower score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Belly Pain 5a</title>
          <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Belly Pain 5a questionnaire has a total score ranging from 1-25 with the lower score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="8.2"/>
                    <measurement group_id="O2" value="7.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Diarrhea 6a</title>
        <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Diarrhea 6a questionnaire has a total score ranging from 1-30 with the lower score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Diarrhea 6a</title>
          <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Diarrhea 6a questionnaire has a total score ranging from 1-30 with the lower score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.4"/>
                    <measurement group_id="O2" value="6.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Nausea and Vomiting 4a</title>
        <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Nausea and Vomiting 4a questionnaire has a total score ranging from 1-20 with the lower score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the PROMIS Scale v1.0 - Gastrointestinal Nausea and Vomiting 4a</title>
          <description>Patient Reported Outcome Measures Information Systems (PROMIS-GI) Gastrointestinal Nausea and Vomiting 4a questionnaire has a total score ranging from 1-20 with the lower score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.8"/>
                    <measurement group_id="O2" value="3.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the PROMIS Scale v2.0 - Ability to Participate in Social Roles and Activities - Short Form 8a</title>
        <description>Patient Reported Outcome Measures Information Systems (PROMIS) Ability to Participate in Social Roles and Activities - Short Form 8a questionnaire has a total score ranging from 8-40 with the lower score indicating a healthier status</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide Intervention</title>
            <description>Participants that received Teduglutide for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Intervention</title>
            <description>Participants that received Standard of Care for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the PROMIS Scale v2.0 - Ability to Participate in Social Roles and Activities - Short Form 8a</title>
          <description>Patient Reported Outcome Measures Information Systems (PROMIS) Ability to Participate in Social Roles and Activities - Short Form 8a questionnaire has a total score ranging from 8-40 with the lower score indicating a healthier status</description>
          <population>This is a cross-over study. Each participant received both teduglutide intervention and the standard of care intervention for 8 weeks each.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="7.8"/>
                    <measurement group_id="O2" value="34.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 19 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>On Teduglutide</title>
          <description>The study is a crossover design. All participants received 8 weeks of daily Teduglutide.&#xD;
Teduglutide: Daily 0.05 mg/kg Teduglutide administered subcutaneously.</description>
        </group>
        <group group_id="E2">
          <title>On Standard of Care</title>
          <description>The study is a crossover design. All participants received 8 weeks of daily Standard of Care Therapy.&#xD;
Standard of Care: The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Right Sided Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stoma hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain at fistula site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Small Bleeding from Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema around ostomy site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>IV Infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. D. Dante Yeh</name_or_title>
      <organization>University of Miami</organization>
      <phone>3055851178</phone>
      <email>dxy154@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

